Minister states no direct link exists between air pollution and lung disease, acknowledging it as a triggering factor for ...
Delhi experienced severe smog on Monday, with the AQI reaching 498 - the city's most polluted day of the winter. Residents ...
GSK’s Nucala receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease
GSK’s Nucala receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease: London, UK Monday, December 15, 2025, 16:00 Hrs [IST] GSK plc announced that ...
Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...
Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...
MedPage Today on MSN
First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...
A greater proportion of women vs. men with COPD or bronchiectasis had their first health care visit within 6 months of ...
With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | Tuesday ...
A Brazilian study involving nearly 900 participants under the age of 40 reinforces the idea that premature lung aging is ...
The FDA has approved Exdensur for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 and older.
Zacks Investment Research on MSN
GSK's Exdensur gets FDA nod for severe asthma treatment
GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as ...
Everyday Health on MSN
RSV vaccine: What you need to know
Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback